Abstract

Objective: The aim of our study is to investigate the antioxidant status, inflammatory parameters, hematologic markers, clinical data of CSU Tunisian patients and the effect of a first-line treatment of CSU, which is Desloratadine 5mg/day on these different parameters. Methods: This study enrolled 30 CSU patients and 30 controls. We assessed antioxidant parameters (Total antioxidant status (TAS) and glutathione S-Transferase (GST)), inflammatory markers (Albumin, Alpha 1, alpha2, beta1 globulins and CRP) and hematolo gic numeration. We assessed the Urticaria Activity Score (UAS). Results: Alpha1, alpha2, beta 1 globulins, CRP, Leucocytes and basophils were significantly increased in patients at baseline versus controls (p<0.05). TAS, GST activity and albumin were significantly decreased in patients at baseline versus controls (p<0.05). TAS and GST activity were significantly increased in patients after treatment versus patients before treatment (p<0.001). Alpha1, alpha2, beta 1 globulins, CRP, albumin, leucocytes and basophils were significantly decreased in patients after treatment versus patients before treatment (p<0.05). A significant correlation between CRP and UAS (r=0.2; p<0.001) was noted. UAS assessment highlighted the efficacy of 30 days-antihistaminic treatment. Conclusion: Our study emphasizes the involvement of oxidative stress in CSU. Interestingly, we found that desloratadine exerted anti-inflammatory and antioxidant effects.